Background: Parenteral nutrition (PN) increases risks of infections in critically injured patients. Recently, PN was shown to reduce intestine luminal levels of the Paneth cell antimicrobial molecule secretory phospholipase A 2 (sPLA 2 ) and the goblet cell glycoprotein mucin2 (MUC2). These molecules are critical factors for innate mucosal immunity and provide barrier protection. Interleukin-4 (IL-4) and IL-13 regulate sPLA 2 and MUC2 production through the IL-13 receptor. Because IL-25 stimulates IL-4 and IL-13 release and PN reduces luminal sPLA 2 and MUC2, we hypothesized that adding IL-25 to PN would restore these innate immune factors and maintain barrier function. Methods: Two days after venous cannulation, male ICR (Institute of Cancer Research) mice were randomized to receive chow (n = 12), PN (n = 9), or PN + 0.7 μg of exogenous IL-25 (n = 11) daily for 5 days. Small-intestine wash fluid (SIWF) was collected for analysis of sPLA 2 activity, MUC2 density, and luminal levels of IL-4 and IL-13. Small-intestinal tissue was harvested for analysis of tissue sPLA 2 activity or immediate use in an ex-vivo intestinal segment culture (EVISC) to assess susceptibility of the tissue segments to enteroinvasive Escherichia coli. Results: PN reduced luminal sPLA 2 (P < 0.0001) and MUC2 (P <0.002) compared with chow, whereas the addition of IL-25 to PN increased luminal sPLA 2 (P < 0.0001) and MUC2 (P < 0.02) compared with PN. Tissue IL-4 and IL-13 decreased with PN compared with chow (IL-4: P < 0.0001, IL-13: P < 0.002), whereas IL-25 increased both cytokines compared with PN (IL-4: P < 0.03, IL-13: P < 0.02). Tissue levels of sPLA 2 were significantly decreased with PN compared with chow, whereas IL-25 significantly increased tissue sPLA 2 levels compared with PN alone. Functionally, more bacteria invaded the PN-treated tissue compared with chow (P < 0.01), and the addition of IL-25 to PN decreased enteroinvasion to chow levels (P < 0.01). Conclusions: PN impairs innate mucosal immunity by suppressing luminal sPLA 2 activity and MUC2 density compared with chow. PN also increases bacterial invasion in ex-vivo tissue. Administration of exogenous IL-25 reverses this dysfunction and increases luminal sPLA 2 and MUC2. PN tissue treated with IL-25 was significantly more resistant to bacterial invasion than with PN alone, suggesting that IL-25-induced effects augment the barrier defense mechanisms.
P arenteral nutrition (PN) allows nutritional support of patients unable to be fed enterally. Unfortunately, PN is associated with an increased risk of infectious complications. [1] [2] [3] [4] Compromise of the intestinal mucosal barrier is believed to be partly responsible for this increased risk. 5 Multiple components of the intestinal mucosal barrier work in concert to prevent bacterial pathogens from attaching to and invading the host tissue. 6 These barrier mechanisms include tight-junction proteins between epithelial cells, mucin glycoproteins secreted by goblet cells, 5, 7 antimicrobial molecules released from Paneth cells, [8] [9] [10] [11] and the release of immunoglobulin-A (IgA) by the epithelium. [12] [13] [14] PN , with lack of enteral stimulation, impairs multiple components of this barrier function, such as luminal IgA produced by acquired (adaptive) immunity through mechanisms previously reported. [15] [16] [17] [18] [19] [20] [21] [22] [23] In addition to impairment of acquired immunity, we recently demonstrated that PN reduced levels of the Paneth cell antimicrobial molecule secretory phospholipase A 2 (sPLA 2) and the goblet cell glycoprotein mucin2 (MUC2) within the gut lumen. 24 Innate immunity is regulated by specialized epithelial cells that sustain mucosal defenses by providing a physical, protective barrier and by producing specialized bioactive molecules. The production and secretion of mucus by goblet cells plays an integral primary role by providing a physical barrier that expands over and protects the mucosa. Paneth cells produce, store and secrete various antimicrobial peptides that neutralize microbes. Importantly, secretory IgA and Paneth cell antimicrobial peptides localize within the mucus layer in high concentrations, which enhances the mucus layer and limits the exposure of microbes to the epithelium. 6, 25 The Th2 cytokines interleukin-4 (IL-4) and IL-13 are important mediators of goblet cell mucus production in the intestine. [26] [27] [28] IL-13 binds to the IL-4 receptor (IL-4R) and the IL-13 receptor (IL-13R) to promote production and release of goblet cell products, including MUC2. Mice develop a lethal colitis in the absence of MUC2 production. 29 Paneth cells produce small antimicrobial proteins, including sPLA 2 , defensins, and lysozymes, which are stored in granules. 8, [30] [31] [32] sPLA 2 specifically provides antimicrobial activity against Gram-positive bacteria. [33] [34] [35] IL-13, via the IL-13R, is necessary to maintain production of antimicrobial peptides, including sPLA 2 , and various other cryptdins in Paneth cells. 28 IL-13 knockout mice produce lower levels of these antimicrobial products compared with mice with intact IL-13 signaling. 28 These products, in part, comprise the mucosal barrier and help prevent invasion of pathogenic bacteria into the bowel epithelium.
IL-25 is a powerful cytokine that amplifies Th2 responses. 36 Exogenous administration of IL-25 upregulates production of the Th2 cytokines IL-4, IL-5, IL-9, and IL-13 37 and attenuates colitis in animal models. Other authors have demonstrated that these cytokines promote Paneth cell and goblet cell hyperplasia, hypertrophy, and secretion, 28 in addition to smooth muscle contraction, 38 resulting in what is described as a "weep and sweep" effect on the mucosa that promotes the clearance of pathogens. 39 Because PN is known to reduce the Th2 cytokines IL-4 and IL-13, and the Paneth and goblet cell products, we hypothesized that adding IL-25 to PN would restore the Th2 response; stimulate innate luminal factors, including goblet cell MUC2 and Paneth cell sPLA 2 ; and restore tissue levels of IL-4 and IL-13. We further hypothesized that loss of these products in PN would result in increased susceptibility to bacterial invasion in an ex-vivo intestinal segment culture (EVISC) and that administration of IL-25 during PN would rescue this phenotype.
MATERIALS AND METHODS Animals
All protocols were approved by the Animal Care and Use Committee of the University of Wisconsin-Madison, and the William S. Middleton Memorial Veterans Hospital, Madison, WI. Male ICR (Institute of Cancer Research) mice were purchased from Harlan (Indianapolis, IN) and housed 5 per covered/filtered box under controlled temperature and humidity conditions with a 12:12-hour light:dark cycle in an American Association for Accreditation of Laboratory Animal Care-accredited conventional facility. Animals were fed standard mouse chow (Rodent Diet 5001; LabDiet, PMI Nutrition International, St. Louis, MO) and water ad libitum for 1 week before initiation of study protocol.
Experimental Design
Male ICR mice, ages 6 to 8 weeks, were randomized to chow with an intravenous catheter (chow, n = 12), PN (n = 12), or PN with 0.7 μg/mouse/day exogenous IL-25 (R&D Systems, Minneapolis, MN) delivered i.v. for 5 days (PN + IL-25, n = 12). Chow-and PN-fed animals also received a saline vehicle control to the IL-25 treatment vehicle. Animals were anesthetized by intramuscular injection, weighed, and underwent placement of silicon rubber catheter (0.012 inch i.d./0.025 inch o.d.; Helix Medical, Inc., Carpinteria, CA) in the vena cava through the right external jugular vein. The catheter was tunneled subcutaneously and exited at the midpoint of the tail. The animals were housed individually and partially immobilized by tail restraint in metabolic cages with wire floors to prevent coprophagia and bedding ingestion to protect the catheter during infusion. This technique has proven to be an acceptable method of nutritional support and does not produce physical or biochemical evidence of stress. The catheterized mice were connected to infusion pumps and received saline (0.9%) at 4 mL/day and ad libitum chow (Agway Inc., Syracuse, NY) and water during the 48 hours of recovery. After 48 hours, chow-fed mice continued to receive 0.9% saline at 4 mL/day as well as ad libitum chow and water. PN-fed animals received PN solution at rates 4 mL/day (day 1), 7 mL/day (day 2), and 10 mL/day (days 3 to 5) because a graded infusion period has been demonstrated to be necessary for the mice to adapt to the glucose and fluid loads. The PN solution contains 6.0% amino acids, 35.6% dextrose, electrolytes, and multivitamins, containing 1440 kcal/L and a nonprotein calories:nitrogen ratio of 128:1. These values were calculated to meet the nutrient requirements of mice weighting 25 to 30 g.
After 5 days of feeding (7 days post catheterization), mice were anesthetized by intraperitoneal injection of ketamine (100 mg/kg) and acepromazine (10 mg/kg), and exsanguinated via left axillary artery transection. The small intestine was removed and the lumen rinsed with 20 mL Hanks Balanced Saline Solution (HBSS; Bio Whittaker, Walkersville, MD). The luminal wash was centrifuged at 2000g for 10 minutes and supernate aliquots were frozen at -80 • C for analysis of sPLA 2 activity, MUC2 densitometry, and luminal IL-4 and IL-13 levels. Tissue samples were taken by removing ileal segments (3 cm) excluding the Peyer patches. These samples were frozen in liquid nitrogen and stored at -80 • C until processing for tissue analysis or used immediately in the EVISC methodology to determine bacterial enteroinvasion.
Continuous Fluorescent Assay for sPLA 2 Activity
Fluorescent assay for sPLA 2 activity was performed as described previously by Tsao et al, 24 with some modification to substrate preparation. This assay uses a specific probe, Bis-BODipy FL, which is designed to fluoresce when the Sn2 position of the phospholipid glyceraldehyde backbone is cleaved. This method was established as a high-throughput method to rapidly analyze sPLA 2 activity, and we have reliably utilized this technique to measure sPLA 2 activity in the small-intestinal tissue and luminal wash fluid. After the reactions reached equilibrium temperature, the reaction curve was fit to a second-order polynomial equation and the first-degree coefficient was taken as the initial rate of reaction [expressed as change in fluorescence (FL)/min/uL sample]. Blank wells containing only substrate and buffer were used to find coefficient rates determined as background activity.
Western Blot for MUC2 in the Small-Intestinal Wash Fluid
Tissue culture medium (5 uL) was denatured at 95 • C for 10 minutes with sodium dodecylsulfate and β-mercaptoethanol and separated in a 4-15% polyacrylamide gel (Ready Gel; Bio-Rad Laboratories, Hercules, CA) by electrophoresis at 150 V for 65 minutes. After electrophoresis, the proteins were transferred to a polyvinylidene fluoride (PVDF) membrane using the standard transfer buffer (Tris-glycine buffer plus 20% methanol) at 80 V for 60 minutes. Membranes were blocked with 5% nonfat dry milk prepared in TBS-Tween (Tris-buffered saline with 0.5% Tween-20) for 1 hour with continuous stirring. The membranes were incubated with the primary antibody mouse anti-human MUC2 (ab-11197; Abcam Inc, Cambridge, MA) diluted 1:2500 overnight at 4 • C with constant rocking. Membranes were washed and incubated with stabilized goat anti-mouse IgG-HRP conjugate (sc-2005; Santa Cruz Biotechnology, CA) diluted 1:20,000 for 1 hour at room temperature with constant agitation. After washing with TBS-tween, membranes were incubated with horse radish peroxidase (HRP) substrate (Super Signal West Femto maximum sensitivity substrate; Pierce, Rockford, IL) for 5 minutes and bands were detected using a photographic film. Densitometric analysis of molecular-weight bands at 260 kDa and 500 kDa were used to measure MUC2 concentration.
Tissue and Luminal Cytokine Quantitative Analysis
Concentrations of IL-4 and IL-13 were measured in the smallintestinal tissue or in the small-intestinal wash fluid (SIWF) using a solid-phase sandwich ELISA (BD Biosciences, San Diego, CA) as previously described. 40 The mass amounts were determined by plotting sample absorbance values on a 4-parameter logistic fit standard curve, as calculated with the SOFTmax PRO software (Molecular Devices, Sunnyvale, CA), and were normalized to total protein content.
Bacterial Preparation
Colonies of Escherichia coli 5011-Lux containing ampicillin resistance were grown in 40 mL lysogeny broth (LB) medium for 48 hours at 37 • under 5% CO 2 , then a surface sample was passed to a new 40 mL LB and grown for 24 hours at 37 • under 5% CO 2 . The surface sample is used since bacteria growing near the culture surface express virulence. Bacteria were spun down at 1780g for 11 minutes, the supernatant was poured off, and the pellet was resuspended in 40 mL LB to wash twice, and then resuspended in 1 mL DPBS at 4 • as a bacteria stock solution. A 1:100 dilution of the bacterial stock solution was made and read on a spectrophotometer (DU640B; Beckman, Krefeld, Germany) at 450-nm wavelength. Bacterial concentrations were adjusted based on growth curves previously established.
Ex-Vivo Intestinal Segment Culture
Intestinal segments were placed on a sterile surface covered in a light layer of RPMI and carefully opened with the apical side up. Tissue glue (Dermabond; Ethicon, Cornelia, GA) was lightly covered on 1 side of a plastic tissue ring and lowered over the intestinal segment. Tissue rings were manufactured from polystyrene with a 9mm diameter and a 6-mm internal aperture. Once the tissue glue had set (approximately 10 seconds), the tissue disk and intestinal segment were turned over. A second tissue disk was lightly covered with tissue glue and placed on the serosal side of the intestinal segment. Once the second tissue disk had adhered, a light layer of tissue glue was applied to the bottom of the serosal disk and the intestinal segment sandwiched between tissue disks was lowered into a cell culture insert (Cat 3292, 3.0 μM pore, 12-well format; BD Bioscience, Franklin Lakes, NJ). Gentle pressure was applied to ensure adherence of the bottom tissue disk to the cell culture insert. Cell culture inserts were placed into 12-well plates prefilled with 1 mL RPMI + ampicillin per well.
A total of 400 μL of bacterial inoculums [1 × 10 8 colony forming units (CFUs)/mL] in RPMI + ampicillin were placed into the wells for 1 hour at 37 • . Then, the bacterial inoculum was collected and centrifuged at 14,000g for 2 minutes to pellet bacteria, and the supernatant was stored for analysis of mucosal secretions. The wells were rinsed gently with 500 μL of DPBS 3 times. Six hundred microliters of RPMI + gentamicin were added to each well for 1 hour at 37 • . This was done to kill any remaining bacteria in the well or adherent to the mucosal surface. RPMI + gentamicin were then removed and the wash step was repeated. Then, 500 μL of 0.1% Triton-X in PBS were added to each well. The 12-well plates were placed on an orbital shaker and agitated (175 rpm; New Brunswick Scientific Classic Series C1 Shaker; New Brunswick Scientific, Edison, NJ) for 30 minutes at room temperature. Serial dilutions (10 1 -10 7 ) of the cell lysate in DPBS were plated on LB + ampicillin agar plates and grown for 18 hours at 37 • . Enteroinvasion was assessed by counting CFUs. The RPMI + ampicillin added to the 12-well plate was also plated to detect cell culture insert leaks. If leaks were detected from the apical to the serosal side, the well was discarded from the experiment.
Statistical Analysis
The data are expressed as means ± standard error of the mean (SEM). Statistical significance was determined using analysis of variance (ANOVA) with the Fisher protected least-significant difference posthoc test or Student t test. Differences were considered to be statistically significant at P < 0.05. All statistical calculations were performed with StatView (Abacus Concepts, Berkeley, CA).
RESULTS

Analysis of Intestinal Fluid sPLA 2
The sPLA 2 activity (FL/min/uL) within the SIWF was significantly lower in the case of PN compared with chow (1895 ± 418 vs. 7811 ± 467, P < 0.0001). The addition of IL-25 to PN significantly increased sPLA 2 activity compared with PN alone (5954 ± 824 vs. 1895 ± 418, P < 0.0001); sPLA 2 was still significantly lower in the case of PN + IL-25-fed versus chow-fed mice (5954 ± 824 vs. 7811 ± 467, P = 0.03) ( Fig. 1 ).
Analysis of Intestinal Fluid MUC-2
The luminal MUC2 (relative density) within the SIWF was significantly depressed in PN-fed mice compared with chow-fed mice (50,366 ± 4059 vs. 75,912 ± 6181, P = 0.001). PN supplementation with IL-25 significantly increased the relative luminal level of MUC2 compared with PN (65,448 ± 4625 vs. 50,366 ± 4059, P = 0.02). There were no significant differences between chow-fed and PN + IL-25-fed mice (75,912 ± 6181 vs. 65,448 ± 4625, P = 0.16) ( Fig. 2 ).
Analysis of Tissue IL-4 and IL-13 Levels
PN significantly reduced tissue levels of IL-13 (pg/mg) compared with chow (PN: 7.9 ± 1.1 vs. chow: 15.1 ± 1.3, P < 0.02) (Fig.  3A) . The addition of IL-25 to PN significantly increased IL-13 tissue levels compared with PN alone (PN + IL-25: 13.8 ± 1.5 vs. PN: 7.9 ± 1.1, P < 0.02) and the IL-13 levels were similar to chow levels (PN + IL-25: 15.1 ± 1.3 vs. chow: 13.8 ± 1.3, P = NS). Consistent with our previous studies, PN significantly decreased the tissue levels of IL-4 compared with chow (PN: 22.4 ± 0.8 pg/mg protein vs. chow: 33.9 ± 2.5 pg/mg protein, P < 0.03) (Fig. 3B ). The addition of IL-25 to PN significantly increased tissue IL-4 compared with PN alone (PN + IL-25: 28.6 ± 1.6 pg/mg protein vs. PN: 22.4 ± 0.8 pg/mg protein, P = 0.03); however, the IL-4 levels remained significantly lower than chow alone (PN + IL-25: 28.6 ± 1.6 pg/mg protein vs. chow: 33.9 ± 2.5 pg/mg protein, P < 0.05). (Fig. 4A, B ).
Analysis of Small-Intestinal Wash Levels of IL-4 and IL-13
Analysis of Tissue sPLA 2
sPLA 2 activity (Fl/min/uL) within the ileum tissue was significantly reduced in PN compared with chow (1895 ± 418 vs. 7811 ± 467, P < 0.0001). The addition of IL-25 to PN significantly increased tissue sPLA 2 activity compared with PN (5954 ± 845 vs. 1895 ± 418, P < 0.0001), but IL-25 was still significantly decreased compared with chow (5954 ± 845 vs. 7811 ± 467, P = 0.03) ( Fig. 5 ).
Bacterial Invasion After EVISC
Ileum segments from PN-fed mice were significantly more susceptible to bacterial invasion (CFUs/segment) than chow segments (20,450 ± 4290 CFU vs. 84,851 ± 24671, P < 0.01). The addition of IL-25 to PN significantly decreased bacterial invasion compared with PN alone (13,497 ± 4400 CFU vs. 84,851± 24,671, P < 0.01) and was statistically similar to bacterial invasion in chow-fed mice (Fig. 6 ).
DISCUSSION
Parenteral nutrition (PN) prevents progressive malnutrition in patients with contraindications to enteral nutrition. Unfortunately, lack of enteral feeding is associated with an increased risk of infectious complications, a risk suspected to be due in part to alterations in the intestinal mucosal barrier. The mucosa is protected by both adaptive (acquired) immunity and innate immunity. Adaptive immunity functions to produce and release IgA at mucosal surfaces. Innate immunity of the mucosal barrier includes the release of antimicrobial molecules from Paneth cells and secreted mucin glycoproteins from goblet cells that cover the epithelial surface. Under normal circumstances, these and other mechanisms successfully defend a surface area of roughly 300 m 2 against dietary and environmental antigens and enormous numbers of bacteria. 5 We previously demonstrated that PN feeding suppresses luminal levels of IgA and the Paneth cell antimicrobial compound, sPLA 2. 24, 41, 42 In addition, we observed PN with lack of enteral stimulation and found that PN reduces the goblet cell-derived mucin layer, which is largely composed of the MUC2 glycoprotein. 5, 7 The current study investigated whether deleterious changes in innate immunity from PN can be corrected via administration of the Th2 cytokine IL-25 during PN feeding.
The Th2 cytokines IL-4 and IL-13 are mediators of goblet cells and mucus production in the intestine. [26] [27] [28] 43 IL-13 interacts with the IL-4R and IL-13R to promote production and release of the glycoprotein MUC2. IL-13 is also a modulator of Paneth cell function, where its interaction with IL-13R is necessary to stimulate production of antimicrobial peptides, including sPLA 2 and the cryptdins. Indeed, IL-13 knockout mice produce low levels of these antimicrobial products. 28 IL-25 is a powerful cytokine that amplifies Th2 responses and appears to be produced by the epithelium itself. 36 Recent experiments demonstrate that exogenous administration of IL-25 attenuates colitis in animal models and upregulates production of the Th2 cytokines IL-4, IL-5, IL-9, and IL-13. 37 Collectively, these studies show that the Th2 profile promotes Paneth and goblet cell hyperplasia, hypertrophy, and secretion, in addition to smooth-muscle contraction. 38, 39 These effects result in the so called "weep and sweep" effect on the mucosa that promotes the clearance of pathogens. 39 We studied the effects of PN and PN + IL-25 on the innate immune products released by 2 types of secreting epithelial cells, Paneth cells and goblet cells, which provide innate defenses for the intestinal mucosa. Goblet cells produce mucin glyoproteins that provide a physical barrier between organisms within the lumen and the epithelial cell layer. The most abundant mucin secreted into the small intestine is MUC2. This large glycoprotein provides a visoelastic surface over which the intestinal contents pass. Paneth cells reside at the base of the intestinal crypts, where they produce, store, and secrete an array of antimicrobial products, including sPLA 2 , lysozymes, and defensins, which provide a chemical defense against luminal microorganisms. 31, 32, 44 sPLA 2 attacks Gram-positive bacteria cell membranes, where it catalytically cleaves phospholipids, inducing membrane disruption and lysis. 44 Interestingly, the many Paneth cell antimicrobial molecules, including sPLA 2 , are cationic and concentrate within the highly anionic MUC2 layer. Together, these molecules form an immunological barrier, preventing attachment of bacteria and compromise of the mucosal epithelium. The importance of these mechanisms is demonstrated in mice lacking either Paneth or goblet cell products. These mice have impaired clearance of infectious organisms and succumb to epithelial inflammation and colitis that may be lethal. 29 The results from this current study are consistent with our previous work which demonstrated that PN significantly reduces luminal levels of the goblet cell product MUC2 and the Paneth cell product sPLA 2. 24 PN also decreases the expression of the Paneth cell product sPLA 2 in tissue homogenates, suggesting Paneth cell function is affected. Because Paneth and goblet cell products are stimulated in part through the Th2 cytokines IL-4 and IL-13, we also assayed these molecules in the tissue and showed that their levels were significantly lower after PN, consistent with our previous reports. This study also shows a reduction in the luminal expression of the Th2 cytokines IL-4 and IL-13. 16, 45 Interestingly, the luminal cytokine levels mirror the tissue levels, suggesting a link between the 2 compartments. Other groups have concluded that luminal cytokines may provide paracrine signals to the epithelium under inflammatory conditions. [46] [47] [48] To our knowledge, this is the first report of changes to luminal cytokines after PN feeding, and we are currently investigating the implications and functions of these and other luminal cytokines in maintenance of immune function.
To determine the stimulatory role of Th2 cytokines upon tissue and luminal levels of these cell products, we exogenously administered the Th2-amplifying cytokine IL-25 during PN. The administration of IL-25 with PN significantly increased tissue sPLA 2 levels, implicating a stimulatory effect on Paneth cells. IL-25 administration to PN also significantly increased the tissue levels of the Th2 cytokines IL-4 and IL-13 compared with PN alone. Finally, the addition of IL-25 to PN also significantly increased luminal levels of sPLA 2 and MUC2 compared with PN alone. This suggests that Th2 cytokines are important for the modulation of these Paneth and goblet cell products. Consistent with the tissue cytokines, luminal IL-4 and IL-13 were also higher in the wash fluid after exogenous IL-25 treatment of PN, further supporting a possible functional role for luminal cytokines.
To determine if IL-25 administration to PN has functional benefit to barrier function, we challenged the small-bowel tissue using an EVISC model designed to quantify bacterial invasion. Consistent with the impaired sPLA 2 and MUC2 levels after PN feeding, small-bowel segments from PN-fed animals had significantly greater enteroinvasion compared with chow-fed animals. Strikingly, compared with PN alone, the addition of exogenous IL-25 to PN significantly decreased bacterial invasion to levels observed in segments of chow-fed animals. Since IL-25 increased luminal levels of sPLA 2 and MUC2, it is likely that these molecules are protective in the ex-vivo model. In this study, sPLA 2 served as a surrogate marker for Paneth cell production in tissue and lumen because sPLA 2 is a constitutively expressed molecule. However, there are other antimicrobial compounds produced and secreted by Paneth cells, including lysozymes, RegIII, Ang-4, and the cryptdins, in addition to sPLA 2 . Further studies are underway to investigate this possibility and further elucidate protective mechanisms of barrier function.
In summary, this study supports the hypothesis that PN with the lack of enteral stimulation induces dysfunctional mucosal barrier responses, as measured through the loss of MUC2, sPLA 2 , and increased susceptibility to Escherichia coli enteroinvasion. Further, this study demonstrates that the Th2-amplifying cytokine IL-25 stimulates production of the cytokines IL-4 and IL-13, and restores the luminal concentrations of sPLA 2 and MUC2, changes that coincide with restored barrier function in our ex-vivo enteroinvasion challenge. Further work is underway to determine contributions of MUC2, sPLA 2 , and other Paneth cell antimicrobials molecules in protection of the mucosal barrier.
